Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.

ABSTRACT:

Background and objectives

Epidemiologic studies suggest that higher serum phosphaturic hormone fibroblast growth factor 23 levels are associated with increase morbidity and mortality. The aim of the FGF23 Reduction Efficacy of a New Phosphate Binder in CKD Trial was to evaluate the effect of sevelamer carbonate on serum C-terminal fibroblast growth factor 23 levels in normophosphatemic patients with CKD stage 3b/4.

Design, setting, participants, & measurements

Patients with CKD, eGFR between 45 and 15 ml/min per 1.73 m², fasting serum phosphate concentration >3.1 mg/dl, and serum C-terminal fibroblast growth factor 23 >80 relative units/ml were included in our double-blind, placebo-controlled, randomized multicenter study. All patients received 100,000 IU cholecal

SUBMITTER: Liabeuf S 

PROVIDER: S-EPMC5718266 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature